FONT-SIZE Plus   Neg

Amgen Reports Top-Line Results Of Phase 3 Sensipar/Mimpara EVOLVE Trial

Amgen Inc. (AMGN) announced top-line results of the Phase 3 EVOLVE trial, evaluating Sensipar/Mimpara for the reduction of the risk of mortality and cardiovascular or CV events among 3,883 patients with secondary hyperparathyroidism and chronic kidney disease receiving dialysis.

The trial's primary endpoint was time to the composite event comprising all-cause mortality or first non-fatal cardiovascular event, including myocardial infarction, hospitalization for unstable angina, heart failure or peripheral vascular event. Though patients in the Sensipar/Mimpara arm experienced numerically fewer composite primary events, the results were not statistically significant, and the study failed to meet its primary endpoint in the intent-to-treat analysis.

"Amgen embarked on the EVOLVE trial to understand whether treating secondary HPT with Sensipar/Mimpara could positively impact the high rates of mortality and cardiovascular events among patients with CKD receiving dialysis," said Sean Harper, M.D., executive vice president of Research and Development at Amgen.

The most frequently reported adverse events in the Sensipar/Mimpara arm of the trial were consistent with the known safety profile of this therapy and included nausea, vomiting and hypocalcemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
General Mills Inc. (GIS) is voluntarily recalling 1.8 million boxes of "gluten-free" Cheerios and Honey Nut Cheerios manufactured at its Lodi, California facility, as it may contain wheat. Wheat was inadvertently mixed into the gluten free oat flour at its facility in Lodi, California. As a result,... Microsoft (MSFT) has unveiled its latest tablet. The technology giant officially debuted the new Surface Pro 4 at its Windows 10 event, held in New York City on Tuesday. The product, meant to draw customers away from laptops, includes a 12.3 inch screen, with a smaller bezel than its Pro 3 predecessor. Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements.
comments powered by Disqus
Follow RTT